By jamesfetzer.org - July 17, 2021
Doctors for Covid Ethics has sent the following letter to tens of thousands of doctors in Europe, summarizing four recent scientific findings critical to the COVID-19 vaccination program. The letter explains each finding as it relates to the biology of COVID-19 vaccines, including interactions with the immune system.
Taken together, the letter warns that these new pieces of evidence force all physicians administering COVID-19 vaccines to re-evaluate the merits of COVID-19 vaccination, in the interests of their own ethical standing, and their patients’ safety and health.
A video explanation of the underlying immunology by Professor Sucharit Bhakdi MD is here:
https://tube.doctors4covidethics.org/videos/watch/7ca43fab-fa9d-46e6-ac7a-a0c739d9e277
With German subtitles here:
https://tube.doctors4covidethics.org/videos/watch/57c4f2be-94dd-404b-a6c1-65156e3e4811
Dear Colleague:
Four recent scientific discoveries are herewith brought to your urgent attention. They alter the entire landscape of the COVID-19 pandemic, and they force us to reassess the merits of vaccination against SARS-CoV-2.
Summary
Rapid and efficient memory-type immune responses occur reliably in virtually all unvaccinated individuals who are exposed to SARS-CoV-2. The effectiveness of further boosting the immune response through vaccination is therefore highly doubtful. Vaccination may instead aggravate disease through antibody-dependent enhancement (ADE).
Discovery 1: SARS-CoV-2 Spike Protein Circulates Shortly After Vaccination
SARS-CoV-2 proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of Moderna mRNA-1273 vaccine [1]. With 11 of the 13, the SARS-CoV-2 spike protein was detected in the blood within only one day after the first vaccine injection.
Significance
Spike protein molecules were produced within cells that are in contact with the bloodstream—mostly endothelial cells—and released into the circulation. This means that a) the immune system will attack those endothelial cells, and b) the circulating spike protein molecules will activate thrombocytes. Both effects will promote blood clotting. This explains the many clotting-related adverse events—stroke, heart attack, venous thrombosis—that are being reported after vaccination.
Discovery 2: Rapid, Memory-Type Antibody Response After Vaccination
Several studies have demonstrated that circulating SARS-CoV-2-specific IgG and IgA antibodies became detectable within 1-2 weeks after application of mRNA vaccines [1–3].
Significance
Rapid production of IgG and IgA always indicates a secondary, memory-type response that is elicited through re-stimulation of pre-existing immune cells. Primary immune responses to novel antigens take longer to evolve and initially produce IgM antibodies, which is then followed by the isotype switch to IgG and IgA.
A certain amount of IgM was indeed detected alongside IgG and IgA in some studies [1,4]. Importantly, however, IgG rose faster than IgM [4], which confirms that the early IgG response was indeed of the memory type. This memory response indicates pre-existing, cross-reactive immunity due to previous infection with ordinary respiratory human coronavirus strains. The delayed IgM response most likely represents a primary response to novel epitopes which are specific to SARS-CoV-2.
Memory-type responses have also been documented with respect to T-cell-mediated immunity [5–7]. Overall, these findings indicate that our immune system efficiently recognizes SARS-CoV-2 as “known” even on first contact. Severe cases of the disease thus cannot be ascribed to lacking immunity. Instead, severe cases might very well be caused or aggravated by pre-existing immunity through antibody-dependent enhancement (ADE, see below).
Discovery 3: SARS-CoV-2 Elicits Robust Adaptive Immune Responses Regardless Of Disease Severity
Serum antibody profiles were reported for 203 individuals following SARS-CoV-2 infection [8]. 202 (>99%) of the participants exhibited SARS-CoV-2 specific antibodies. With 193 individuals (95%), these antibodies prevented SARS-CoV-2 infection in cell culture and also inhibited binding of the spike protein to the ACE2 receptor. Furthermore, CD8+ T-cell responses specific for SARS-CoV-2 were clear and quantifiable in 95 of 106 (90%) HLA-A2-positive individuals.
Significance
This study confirms the above assertion that the immune response to initial contact with SARS-CoV-2 is of the memory type. In addition, it shows that this reaction occurs with almost all individuals, and particularly also with those who experience no manifest clinical symptoms.
The goal of the vaccination is to stimulate production of antibodies to SARS-CoV-2, but we now know that such antibodies can and will be rapidly generated by everyone upon the slightest viral challenge, even without vaccination.
Severe lung infections always take many days to develop, which means that if the antibodies generated by the memory response are needed, they will arrive on time. Therefore, vaccination is unlikely to provide significant benefit with respect to the prevention of severe lung infection.
Discovery 4: Rapid Increase Of Spike Protein Antibodies After The Second Injection Of MRNA Vaccines
IgG and IgA antibody titres were monitored before vaccination and after the first and the second injection of mRNA vaccines [3]. Antibody titres rose with some delay after the first injection, then plateaued, but rose again very shortly after the second injection.
Significance . . .
[SNIP]
